摘要
目的探讨瑞舒伐他汀在治疗冠心病时,对患者脂代谢和炎症指标的影响,为评价其临床疗效提供基础数据。方法选取2018年8月至2019年6月因冠心病入治阳江市人民医院心血管内科的患者,随机分为常规治疗组和瑞舒伐他汀组,各105例。观察药物相关不良反应发生情况,以及治疗前后的总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)以及肿瘤坏死因子-(TNF-)、白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)、C-反应蛋白(CRP)的变化情况。结果瑞舒伐他汀组和常规治疗组不良反应发生率分别为7.61%(8/105)和6.67%(7/105),差异无统计学意义(P>0.05)。治疗前,两组脂代谢和炎症指标的差异均无统计学意义(P>0.05),治疗后,两组各项指标均有所改善(P<0.05),且瑞舒伐他汀组的TC、TG、LDL-C以及TNF-α、IL-6、MMP-9及CRP水平均低于常规治疗组,而HDL-C水平高于常规治疗组,差异具有统计学意义(P<0.05)。结论瑞舒伐他汀能有效改善冠心病患者的血脂及炎症水平,可起到稳定斑块、抗炎、延缓动脉粥样硬化发展,全面防治心脑血管的疾病作用。
Objective To explore the effect of rosuvastatin on lipid metabolism and inflammation in patients with coronary heart disease,and to provide basic data for the evaluation of its clinical efficacy.Methods From August 2018 to June 2019,patients admitted to the cardiovascular department of Yangjiang People′s Hospital due to coronary heart disease were randomly divided into conventional treatment group and rosuvastatin group,105 cases each.Observe of adverse drug reactions during treatment.The changes of TC,TG,LDL-C,HDL-C,TNF-,IL-6,MMP-9 and CRP were observed before and after treatment.Results There was no significant difference between the two groups(P>0.05).Before treatment,there was no significant difference in lipid metabolism and inflammation between the two groups(P>0.05).The levels of TC,TG,LDL-C,TNF-α,IL-6,MMP-9 and CRP in rosuvastatin group were lower than those in the conventional treatment group,while the levels of HDL-C were higher than those in the conventional treatment group(P<0.05).Conclusion Rosuvastatin can effectively improve the blood lipid and inflammation level of patients with coronary heart disease,stabilize plaque,anti-inflammatory,delay the development of atherosclerosis,and prevent and treat cardiovascular and cerebrovascular diseases in an all-round way.
作者
阮敏
莫北溪
郑伊颖
杨方权
RUAN Min;MO Bei-xi;ZHENG Yi-ying;YANG Fang-quan(Yangjiang People′s Hospital,Yangjiang 529500,China)
出处
《延安大学学报（医学科学版）》
2020年第1期46-48,共3页
Journal of Yan'an University:Medical Science Edition
关键词
瑞舒伐他汀
冠心病
脂代谢
炎性指标
Rosuvastatin
Coronary heart disease
Lipid metabolism
Inflammatory index
作者简介
阮敏(1985-),女,广东阳江人,主治医师。研究方向:心血管内科。
